[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100643414":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":30,"centralContacts":34,"locations":40,"responsibleParty":54,"collaborators":10,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":10,"eligibilityCriteria":62,"healthyVolunteers":58,"sex":63,"minAge":64,"maxAge":65,"enrollmentInfo":66,"targetDuration":10,"studyType":69,"phases":10,"briefSummary":70,"conditions":71,"keywords":73,"overallStatus":42,"whyStopped":10,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Novartis","INDUSTRY",[8,12,15,18,21,24,27],{"label":9,"type":10,"description":11,"interventionNames":10},"Overall GEP-NET Cohort",null,"Adult patients newly diagnosed with a GEP-NET between 01 January 2018 and 31 December 2025.",{"label":13,"type":10,"description":14,"interventionNames":10},"1L Lutetium Lu 177 Dotatate Cohort","A subgroup of the Overall GEP-NET Cohort. Patients receiving 1L lutetium Lu 177 dotatate.",{"label":16,"type":10,"description":17,"interventionNames":10},"1L Capecitabine + Temozolomide (CAPTEM) Cohort","A subgroup of the Overall GEP-NET Cohort. Patients receiving 1L CAPTEM.",{"label":19,"type":10,"description":20,"interventionNames":10},"1L Cabozantinib Cohort","A subgroup of the Overall GEP-NET Cohort. Patients receiving 1L cabozantinib.",{"label":22,"type":10,"description":23,"interventionNames":10},"Lutetium Lu 177 Dotatate Cohort","A subgroup of the Overall GEP-NET Cohort. Patients receiving lutetium Lu 177 dotatate in 2L or later settings.",{"label":25,"type":10,"description":26,"interventionNames":10},"CAPTEM Cohort","A subgroup of the Overall GEP-NET Cohort. Patients receiving CAPTEM in 2L or later settings.",{"label":28,"type":10,"description":29,"interventionNames":10},"Cabozantinib Cohort","A subgroup of the Overall GEP-NET Cohort. Patients receiving cabozantinib in 2L or later settings.",[31],{"name":32,"affiliation":32,"role":33},"Novartis Pharmaceuticals","STUDY_DIRECTOR",[35,39],{"name":32,"role":36,"phone":37,"phoneExt":10,"email":38},"CONTACT","+41613241111","novartis.email@novartis.com",{"name":32,"role":36,"phone":10,"phoneExt":10,"email":10},[41],{"facility":5,"status":42,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":10},"RECRUITING","East Hanover","New Jersey","07936","United States","US",{"type":49,"coordinates":50},"Point",[51,52],-74.36487,40.8201,{"lat":52,"lon":51},{"type":55,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100643414","a-study-of-treatment-patterns-and-outcomes-in-gastroenteropancreatic-neuroendocrine-tumor-gep-net-patients-100643414",false,"NCT07635316","A Study of Treatment Patterns and Outcomes in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients","Treatment Patterns and Outcomes in GEP NET: A Retrospective Observational Cohort Study (PRIME Initiative)","Inclusion criteria:\n\n1. Patients with ≥1 International Classification of Diseases Clinical Modification, 10th revision (ICD-10-CM) diagnosis code for GEP-NET between 01 January 2018 and 31 December 2025. The date of the first such claim will be defined as the diagnosis date.\n2. Initiation of first-line (1L) systemic therapy (i.e., somatostatin analogs \\[SSAs\\], targeted therapy, peptide receptor radionuclide therapy \\[PRRT\\], chemotherapy) indicated for GEP-NET on or after the date of diagnosis. The date of treatment initiation will be defined as the index date.\n3. Patients ≥18 years of age on the index date\n4. Patients with ≥12 months (360 days) of continuous data availability (proxy for continuous health plan enrollment) prior to the index date, defined as:\n\n   1. ≥1 medical and pharmacy claim \\>12 months prior to the index date; AND\n   2. ≥1 medical and pharmacy claim within the first 6 months of the 12-month period prior to the index date; AND\n   3. ≥1 medical and pharmacy claim during the last 6 months of the 12-month period prior to the index date; AND\n5. Patients with ≥1 month (30 days) of continuous data availability (proxy for continuous health plan enrollment) following the index date, defined as:\n\n   1. ≥ 1 pharmacy dispensing a GEP-NET treatment at any time during the post-index period, including the index date, reports data during the first month following the index date\n   2. ≥ 1 provider prescribing a GEP-NET treatment at any time during the post-index period, including the index date, reports data during the first month following the index date\n\nExclusion criteria:\n\n1. Patients with evidence of GEP-NET prior to the diagnosis date within the study period\n2. Patients with evidence of GEP-NET treatment prior to the index date within the study period\n3. Patients with missing or invalid age or sex\n4. Patients with other primary malignancies during the 12-month pre-index period\n5. Patients with invalid death date (i.e., death date ≤ index date)","ALL","18 Years","110 Years",{"count":67,"type":68},4023,"ESTIMATED","OBSERVATIONAL","This study aims to characterize current treatment patterns and clinical outcomes among newly diagnosed GEP-NET patients in the United States using open-source Longitudinal Prescription Claims (LRx) and Patient Centric Medical Claims (Dx) databases supplemented with mortality data.",[72],"Gastroenteropancreatic Neuroendocrine Tumor",[74,75,76],"Real-world evidence","Treatment patterns","Lutathera","2026-07-01",{"date":79,"type":80},"2026-07-06","ACTUAL",{"date":82,"type":80},"2026-06-12",{"date":84,"type":68},"2027-02-25",{"name":32,"class":6},1]